Skip to content

Clinical study on Knee Osteoarthritis.

A Randomized, Parallel group, Open label, Active controlled clinical study to evaluate the safety and efficacy of a Unani Formulation in the management of Waja al mafasil Rukba (Knee Osteoarthritis) - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/082302
Enrollment
50
Registered
2025-03-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M170- Bilateral primary osteoarthritis of knee

Interventions

Intervention1: Oral Unani Formulation(pills): Unani Formulation Containing Sibr zard(Aloe barbadensis),Safoof Amla(Emblica officinalis), Safoof Haleela(Terminalia chebula), Gogul(Commiphora mukul) wil

Sponsors

National Research Institute of Unani Medicine for Skin Disorders
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants of any gender(male and female) in the age group of (50-70)years. Participant having Knee Pain Osteophytes on Knee Radiograph, Morning Stiffness lasting upto 30 minutes and Crepitus on Active Knee Motion. Body Mass Index below 40 kilogram per meter square. Participants willing to sign the ICF and comply with the protocol.

Exclusion criteria

Exclusion criteria: The following participants will be excluded from the study: Participants aged less than (50 years) and more than( 70 years) Systemic and metabolic illnesses like IHD, TB, and Malignancy. Patients with Knee pain other than osteoarthritis. Patients with Osteoarthritis affecting joints other than the knee joint. History of Knee injury, surgery, steroid injection in knee joints Pregnancy and lactation Patients under treatment of steroids Morbid Obesity BMI more than 40

Design outcomes

Primary

MeasureTime frame
Reduction in the total Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC Modified CRD Pune version)Timepoint: At baseline 7th,14th,21st and 28th days

Secondary

MeasureTime frame
Reduction in Pain intensity as per WOMAC (Modified CRD Pune version) pain scale Reduction in stiffness as per WOMAC (Modified CRD Pune version) stiffness scale Reduction in Restrictions of movements as per WOMAC (Modified CRD Pune version) physical activity scaleTimepoint: At baseline and 28th day

Countries

India

Contacts

Public ContactMomin Sarwat Iram Momin Masood Arif

National Research Institute of Unani Medicine for Skin Disorders

Qamaruddindr@gmail.com8700027178

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026